EBOS Group (EBOSY) Fair Value & Analysis
Healthcare · US · Market cap $2.7B
EBOS Group
EBOSY · US
Fair value as of: Jul 16, 2026
From 26 valuation models · updated 7 days ago
Fair value updated Jul 16, 2026, revised from $25.99 to $26.66 (+2.6%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $24.21 – $39.72 · fair‑value band $16.51 – $33.40 · the $26.00 price screens below the $26.66 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
EBOS Group (EBOSY) currently trades at $26.00, while our model-based Fair Value estimate is $26.66, implying the stock looks roughly 2.5% fairly valued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, EBOS Group generated revenue of $13.0B at a net margin of 1.8%. Revenue grew 13.0% year over year. It earns a return on equity of 9.0%. Net debt stands at $1.4B. Fundamentals as of Jul 16, 2026
Our scenario range runs from $16.51 (bear case) to $33.40 (bull case); at $26.00, the current price sits within that range. The share trades about 41% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 16% fair-value upside, at 3%, EBOSY screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. Further, it offers healthcare distribution, warehousing, clinical trial management, and product registration …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
EBOS Group reported revenue of $12.2B in FY2025 versus $9.2B in FY2021, a compound +7.3%/yr. Reported net income was $214M in FY2025, compounding +3.6%/yr from FY2021.
Is EBOSY fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc COR | $281.24 | $168.24 | -40% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Henry Schein, Inc HSIC | $78.67 | $67.77 | -14% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥56.73 | +255% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALNF | $115.00 | $98.28 | -15% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.69 | ¥25.18 | +16% |
| Medipal Holdings MEPDF | $18.35 | $23.62 | +29% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is EBOS Group (EBOSY) undervalued?
What is the fair value of EBOSY?
What is the quality score of EBOSY?
What is the revenue of EBOS Group (EBOSY)?
What is the net profit margin of EBOSY?
Does EBOS Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full EBOS Group analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.